纵向肠道微生物群失生症是奥兰扎诱导的体重增加的基础
Li Qian1,2,3, Xiaoyan He1,2,3, Yixin Liu1,2,3
1Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
通过改变肠道微生物群,olanzapine治疗会导致显著的体重增加和代谢变化. 特定的细菌系如Enterorhabdus和Parasutterella与这种体重增加相关,表明肠道微生物群是潜在的治疗标.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 微生物学和肠道健康
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 奥兰沙平是精神分裂症谱系障碍的关键抗精神病药物.
- 奥兰沙平与显著的体重增加和代谢副作用有关.
- 肠道微生物群影响代谢疾病的发展.
研究的目的:
- 调查肠道微生物群在奥兰zapine引起的肥胖和代谢异常中的作用.
- 为了探索在奥兰扎治疗期间肠道微生物群组成的纵向变化.
主要方法:
- 在接受 olanzapine 治疗的雌性Sprague-Dawley大鼠中进行了纵向研究.
- 对代谢和炎症标志物的测量.
- 分析肠道微生物群的组成和纵向轨迹,使用模糊的c-means集群.
主要成果:
- 奥兰沙平诱导显著的体重增加 (高达2.1倍) 和增加的血甘油三水平 (高达2.9倍).
- 奥兰扎治疗导致肝炎和肠道微生物群失调.
- 包括Enterorhabdus,Parasutterella和Prevotellaceae在内的属UCG-001与体重增加正相关.
结论:
- 奥兰扎直接改变肠道微生物群,诱导与体重增加相关的失活性.
- 特定的肠道细菌和代谢途径与奥兰扎诱导的肥胖有关.
- 准肠道微生物群可能提供一种策略来管理奥兰扎的代谢副作用.
更多相关视频
08:14A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
